Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch

Medicina (Lithuania)

Volumn 51, Issue 3, 2015, Pages 133-145

  Mozuraitiene, Julija ^a   Bielskiene, Kristina ^b   Atkočius, Vydmantas ^a   Labeikyte, Danute ^b  

^a NATIONAL CANCER INSTITUTE   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

MDM2 E3 ubiquitin ligase; MDM4 E3 ubiquitin ligase; Melanoma; Notch pathway; P53 pathway

Indexed keywords

EID: 84964270288     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medici.2015.06.002     Document Type: Review

References (84)

1. Erickson C, Driscoll MS. Melanoma epidemic: facts and controversies. Clin Dermatol 2010;28:281-6.
2. Kurtinaitis J, Aleknavičiene˙ B. Pagrindiniai onkologine˙s pagalbos rezultatai Lietuvoje 1998 m Lietuvos ve˙žio registras [The main results of oncological treatment in Lithuania in 1998: Lithuanian registry of cancer. Vilnius]. 2000.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
4. Bhatia Sh, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009;23:488-96.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
6. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus DTIC for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
8. Medina T, Amaria MN, Jimeno A. Dabrafenib in the treatment of advanced melanoma. Drugs Today 2013;49(6):377.
9. Kainthla R, Kim KB, Falchook GS. Dabrafenib for treatment of BRAF-mutant melanoma. Pharmacogenomics Pers Med 2014;7:21-9.
10. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31(4):482-9.
11. Grob JJ, Jouary T, Dréno B, Asselineau J, Gutzmer R, Hauschild A, et al. Adjuvant therapy with pegylated interferon a-2b (36 months) versus low-dose interferon a-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer 2013;49:166-74.
12. Di Trolio R, Simeone E, Di Lorenzo G, Grimaldi AM, Romano A, Ayala F, et al. Update on PEG-interferon a-2b as adjuvant therapy in melanoma. Anticancer Res 2012;32(9):3901-9.
13. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009;27:2916-23.
14. Kefford RF. Drug treatment for melanoma: progress, but who pays? Med J Austria 2012;197(4):198-9.
15. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703.
16. Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res 2014;28.
17. McArthur GA. Adjuvant interferon in melanoma: is duration of therapy important? J Clin Oncol 2014;32(3):171-3.
18. Panayi ND, Mendoza EE, Breshears ES, Burd R. Aberrant Death Pathways in Melanoma. In Tech; 2013, http://creativecommons.org/licenses/by/3.0.
19. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 2012;18(8):1239-47.
20. Vassilev LT. DM2 inhibitors for cancer therapy. Trends Mol Med 2006;13(1):23-30.
21. Müller CS. Notch signaling malignant melanoma. Advant Exp Med Biol 2012;727:258-64.
22. Nair JS, Sheikh T, Ho AL, Schwartz GK. PTEN regulates sensitivity of melanoma cells to RO4929097, the g-secretase inhibitor. Anticancer Res 2013;33(4):1307-16.
23. Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS ONE 2011;6(9):e25264.
24. Fecher L, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183-9.
25. Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012;2012:354191.
26. Kudchadkar R. Novel targeted therapies for the treatment of metastatic melanoma. Ochsner J 2010;10(2):117-24.
27. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012;10:85.
28. Palmieri G, Colombino M, Sini MC, Ascierto PA, Lissia A, Cossu A. Targeted Therapies in Melanoma: Successes and Pitfalls. Licensee In Tech; 2013. http://dx.doi.org/10.5772/53624, This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0)
29. Bertolotto C. Melanoma: from Melanocyte to Genetic Alterations and Clinical Options. Hindawi Publishing Corporation Scientifica; 2013. p. 1-22.
30. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012;26(11):1131-55.
31. Held MA, Bosenberg MW. Genetic alterations in malignant melanoma. Diagn Histopathol 2010;16(7):317-20.
32. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011;17(2):229-35.
33. Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 2011;44:165-9.
34. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2011;44:133-9.
35. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.
36. Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014;27(4):590-600.
37. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J 2012;8(2):142-7.
38. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS ONE 2012;7(8).
39. Chi M, YanYe Y, Zhang XD, Chen J. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des Dev Ther 2014;8:255-62.
40. Ochoa-Hernández AB, Juárez-Vázquez C, Rosales-Reynoso MA, Barros-Nunez P. WNT-b-catenin signaling pathway and its relationship with cancer. Circulating Cir 2012;80(4):389-98.
41. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, et al. Wnt/b-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 2012;5(206):ra3.
42. Conrad W, Major MB, Cleary MA, Ferrer M, Roberts B, Marine S, et al. FAM129B is a novel regulator of Wnt/bcatenin signal transduction in melanoma cells. Version 2 F1000Res 2013;2:134.
43. Domingues MJ, Rambow F, Job B, Papon L, Liu W, Larue L, et al. b-Catenin inhibitor ICAT modulates the invasive motility of melanoma cells. Cancer Res 2014;74(7):1-13.
44. Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, et al. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/b-catenin signaling. PLoS ONE 2014;9(4):e94748.
45. Kopan R. Notch signaling. Cold Spring Harb Percpectives Biol 2012;4:a011213.
46. Moretti J, Brou Ch. Ubiquitinations in the Notch signaling pathway. Int J Mol Sci 2013;14:6359-81.
47. Fortini ME. Notch Signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-47.
48. Nakayama K. Growth and progression of melanoma and non-melanoma skin cancers regulated by ubiquitination. Pigment Cell Melanoma Res 2010;23(3):338-51.
49. Pettersson S, Sczaniecka M, McLaren L, Russell F, Gladstone K, Hupp T, et al. Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signalling pathway. Biochem J 2013;450(3):523-36.
50. Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia, Galimberti V, Viale G, et al. NUMB controls p53 tumour suppressor activity. Nature 2008;451:76-80.
51. Thelu J, Rossio P, Favier B. Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol 2002;2:7.
52. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013;34(7):1420-30.
53. Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Res 2007;20:458-65.
54. Balint K, Xiao M, Pinnix ChC, Soma A, Veres I, Juhasz I, et al. Activation of Notch1 signaling is required for b-cateninmediated human primary melanoma progression. J Clin Invest 2005;115(11):3166-76.
55. Massi D, Tarantini F, Franchi A, Paglierani M, Di Serio C, Pellerito S, et al. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 2006;19(2):246-54.
56. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ, et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009;69(13):5312-20.
57. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and upregulating N-cadherin expression. Cancer Res 2006;66(8):4182-90.
58. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L, et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 2010;70(24):10340-5.
59. Hasty P, Christy BA. p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis 2013;3:22702.
60. Liu W, Peng Y, Tobin DJ. A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis. Peer J 2013;1:e49.
61. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355(13):1307-17.
62. Verma S, Petrella T, Hamm C, Bak K, Charette M, Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline. Curr Oncol 2008;15(2):85-9.
63. Fricker J. New era in metastatic melanoma. Mol Oncol 2010;4:91-7.
64. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K, et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33(5):484-96.
65. Hamid O, Boasberg PD, Rosenthal K, O'Day SJ. Systemic treatment of metastatic melanoma: new approaches. J Surg Oncol 2011;104(4):425-9.
66. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010;21(7):vii339-44.
67. Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. Pharmacoeconomics 2013;31(12):1121-9.
68. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207.
69. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomized controlled trials. Lancet 2012;380:358.
70. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. An update on BREAK-3, a phase III, randomized trial: dabrafenib versus DTIC in patients with BRAF V600E-positive mutation metastatic melanoma. J Clin Oncol 2013;31 (suppl; abstr 9013).
71. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68:4853-61.
72. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72.
73. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724.
74. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
75. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011;480:387-90.
76. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen A, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011;71:2750-60.
77. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
78. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013;3:158-67.
79. Jang S, Atkins MB. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther 2014;95(1):24-31.
80. Luke JJ, Hodi FS. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res 2012;18(1):9-14.
81. Bedogni B. Notch signaling in melanoma: interacting pathways and stromal influences that enhance Notch targeting. Pigment Cell Melanoma Res 2013;27:162-8.
82. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8.
83. Rajabi P, Karimian P, Heidarpour M. The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma. J Res Med Sci 2012;17(5):452-5.
84. Sczaniecka M, Gladstone K, Pettersson S, McLaren L, Huart AS, Wallace M. MDM2 protein-mediated ubiquitination ofnumb protein:identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem 2012;287(17):14052-68.